Roumen Nakov
Holzkirchen, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Superior physical and mental health of healthy volunteers before and five years after mobilized stem cell donation.
Journal: Journal of translational medicine
Published: August 06, 2021
Meta-analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim.
Journal: Clinical pharmacology in drug development
Published: September 09, 2020
A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics.
Journal: British journal of clinical pharmacology
Published: August 13, 2019
Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 13, 2018
Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects.
Journal: British journal of clinical pharmacology
Published: March 16, 2018
Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 23, 2017
Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.
Journal: Future oncology (London, England)
Published: April 29, 2017
Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
Journal: Future oncology (London, England)
Published: March 30, 2016
A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
Journal: The oncologist
Published: January 11, 2016
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 27, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026